{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:19:52Z","timestamp":1784204392274,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106995","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:07:59Z","timestamp":1768291679000},"page":"106995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Post-infusion observation of patients with multiple sclerosis receiving natalizumab: Is it necessary?"],"prefix":"10.1016","volume":"107","author":[{"given":"Melika Arab","family":"Bafrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar Sadat","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme Zahra","family":"Idjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Bordbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Jahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayhane","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Kamali","family":"Zonouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa Mohammadi","family":"Lapevandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ebadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Navardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hora","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.106995_bib0005","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2026.106995_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117622","article-title":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic","volume":"429","author":"Bringeland","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2026.106995_bib0001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.msard.2026.106995_bib0006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2026.106995_bib0014","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1212\/NXI.0000000000000047","article-title":"Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles","volume":"1","author":"de la Hera","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"7","key":"10.1016\/j.msard.2026.106995_bib0010","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin. Transl. Immunol"},{"key":"10.1016\/j.msard.2026.106995_bib0024","unstructured":"European Medicines Agency. Tysabri (natalizumab): summary of product characteristics (SmPC) [Internet]. 2020 [cited 2025 Nov 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.msard.2026.106995_bib0029","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1212\/NXI.0000000000000706","article-title":"Natalizumab wearing-off effect: the hunt for the elusive pharmacodynamic biomarker","volume":"7","author":"Foley","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2026.106995_bib0007","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS. Drugs"},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.106995_bib0018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jneuroim.2007.04.006","article-title":"Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies","volume":"187","author":"Gold","year":"2007","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2026.106995_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.106995_bib0015","first-page":"1","article-title":"The safety of Natalizumab administration in the home during the COVID-19 pandemic for patients with multiple sclerosis","volume":"2","author":"Health","year":"2023","journal-title":"Infus. J"},{"issue":"4","key":"10.1016\/j.msard.2026.106995_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000382130","article-title":"Multiple Sclerosis Relapses: epidemiology, outcomes and management. A systematic review","volume":"44","author":"Kalincik","year":"2015","journal-title":"Neuroepidemiology."},{"issue":"3\u20134","key":"10.1016\/j.msard.2026.106995_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2026.106995_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251372752","article-title":"Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook","volume":"18","author":"Klotz","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.106995_bib0011","first-page":"753","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurother. J. Am. Soc. Exp. Neurother"},{"key":"10.1016\/j.msard.2026.106995_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103345","article-title":"Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection","volume":"57","author":"Landi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2026.106995_bib0023","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1177\/1352458519860415","article-title":"Infusion-related events during natalizumab: no need for post-infusion monitoring","volume":"26","author":"Loonstra","year":"2020","journal-title":"Mult. Scler. Houndmills Basingstoke Engl"},{"key":"10.1016\/j.msard.2026.106995_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2025.149788","article-title":"Fatigue in natalizumab-treated Multiple Sclerosis patients: how much is wearing-off to blame?","volume":"1864","author":"Magro","year":"2025","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.msard.2026.106995_bib0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O\u2019Connor","year":"2014","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.106995_bib0019","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.106995_bib0008","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.106995_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102642","article-title":"Fast and safe: optimising multiple sclerosis infusions during COVID-19 pandemic","volume":"47","author":"Rath","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2026.106995_bib0012","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.106995_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101523","article-title":"Infusion-related reactions during Natalizumab treatment: do we still need a post-infusion observation period?","volume":"38","author":"Sacco","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2026.106995_bib0004","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (Tysabri)","volume":"31","author":"Selewski","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2026.106995_bib0021","year":"2019","journal-title":"Tysabri (natalizumab) Injection, For Intravenous Use \u2014 Prescribing Information [Internet]"},{"issue":"14","key":"10.1016\/j.msard.2026.106995_bib0002","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. Houndmills Basingstoke Engl"},{"issue":"5","key":"10.1016\/j.msard.2026.106995_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1590\/0004-282x-anp-2020-0303","article-title":"Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile","volume":"79","author":"Ysrraelit","year":"2021","journal-title":"Arq. Neuropsiquiatr."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:49:27Z","timestamp":1780415367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"alternative-id":["S2211034826000313"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106995","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-infusion observation of patients with multiple sclerosis receiving natalizumab: Is it necessary?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106995"}}